Takeda Pharmaceutical (NYSE:TAK) Raised to Strong-Buy at Zacks Research

Takeda Pharmaceutical (NYSE:TAK) was upgraded by equities researchers at Zacks Research from a “hold” rating to a “strong-buy” rating in a research report issued on Wednesday, Zacks reports.

TAK has been the subject of several other research reports. Weiss Ratings downgraded shares of Takeda Pharmaceutical from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, July 30th. Wall Street Zen upgraded shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday, July 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy”.

Takeda Pharmaceutical Trading Up 1.5%

NYSE TAK opened at $18.71 on Wednesday. The firm has a market capitalization of $59.95 billion, a P/E ratio of 55.03 and a beta of -0.07. The business has a fifty day simple moving average of $17.26 and a 200 day simple moving average of $17.20. Takeda Pharmaceutical has a 12 month low of $12.99 and a 12 month high of $18.90. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.95 earnings per share for the quarter, beating the consensus estimate of $0.41 by $0.54. The business had revenue of $7.50 billion for the quarter, compared to analysts’ expectations of $7.13 billion. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, analysts predict that Takeda Pharmaceutical will post 1.54 EPS for the current fiscal year.

Insider Activity

In other news, insider Andrew Plump sold 19,651 shares of the firm’s stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $18.49, for a total transaction of $363,346.99. Following the completion of the sale, the insider directly owned 261,656 shares of the company’s stock, valued at $4,838,019.44. This trade represents a 6.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Anne Furney sold 30,868 shares of Takeda Pharmaceutical stock in a transaction on Monday, August 10th. The stock was sold at an average price of $17.10, for a total value of $527,842.80. Following the sale, the general counsel owned 204,298 shares in the company, valued at $3,493,495.80. The trade was a 13.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 476,731 shares of company stock worth $8,192,525. 0.04% of the stock is owned by insiders.

Institutional Trading of Takeda Pharmaceutical

Several hedge funds have recently added to or reduced their stakes in TAK. Capital Research Global Investors grew its position in shares of Takeda Pharmaceutical by 0.6% during the 4th quarter. Capital Research Global Investors now owns 13,486,772 shares of the company’s stock valued at $210,259,000 after acquiring an additional 82,643 shares during the period. UBS Group AG lifted its stake in Takeda Pharmaceutical by 46.4% in the third quarter. UBS Group AG now owns 5,893,969 shares of the company’s stock valued at $86,288,000 after purchasing an additional 1,869,323 shares during the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Takeda Pharmaceutical by 100.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 5,682,847 shares of the company’s stock valued at $88,596,000 after purchasing an additional 2,854,069 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Takeda Pharmaceutical by 15.0% during the first quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock valued at $79,120,000 after purchasing an additional 692,404 shares during the period. Finally, Renaissance Technologies LLC grew its holdings in Takeda Pharmaceutical by 14.2% during the first quarter. Renaissance Technologies LLC now owns 2,989,100 shares of the company’s stock valued at $55,358,000 after purchasing an additional 370,800 shares during the period. Institutional investors own 9.17% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.